ML261
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ML261, covering 2026-04-01 to 2026-04-01. Get the full timeline:
Most recent: Clinical Trial Update: A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) [Phase 1]